Intellia Therapeutics, Inc. (NASDAQ:NTLA - Free Report) - Equities researchers at Leerink Partnrs issued their Q1 2025 earnings per share (EPS) estimates for shares of Intellia Therapeutics in a research report issued on Thursday, February 27th. Leerink Partnrs analyst M. Foroohar anticipates that the company will earn ($1.39) per share for the quarter. The consensus estimate for Intellia Therapeutics' current full-year earnings is ($5.07) per share. Leerink Partnrs also issued estimates for Intellia Therapeutics' Q2 2025 earnings at ($1.17) EPS and FY2026 earnings at ($4.82) EPS.
Other equities research analysts have also recently issued reports about the company. Wells Fargo & Company decreased their price objective on Intellia Therapeutics from $60.00 to $50.00 and set an "overweight" rating for the company in a research note on Friday. Canaccord Genuity Group reiterated a "buy" rating and issued a $90.00 price target on shares of Intellia Therapeutics in a research note on Tuesday, November 19th. William Blair reissued a "neutral" rating and issued a $14.00 price objective on shares of Intellia Therapeutics in a report on Monday, November 18th. Wedbush reissued a "neutral" rating and issued a $10.00 price objective (down from $14.00) on shares of Intellia Therapeutics in a report on Friday, January 10th. Finally, StockNews.com raised Intellia Therapeutics to a "sell" rating in a report on Friday, November 8th. Two investment analysts have rated the stock with a sell rating, six have given a hold rating, ten have assigned a buy rating and one has assigned a strong buy rating to the company's stock. According to data from MarketBeat, Intellia Therapeutics presently has a consensus rating of "Moderate Buy" and a consensus target price of $42.12.
Read Our Latest Stock Report on Intellia Therapeutics
Intellia Therapeutics Stock Down 6.3 %
Shares of NASDAQ NTLA traded down $0.64 during mid-day trading on Monday, reaching $9.45. 2,998,270 shares of the company were exchanged, compared to its average volume of 3,289,680. The stock has a market cap of $962.47 million, a price-to-earnings ratio of -1.74 and a beta of 1.80. Intellia Therapeutics has a 1 year low of $8.96 and a 1 year high of $33.28. The firm has a 50-day moving average of $10.85 and a 200 day moving average of $15.55.
Insider Buying and Selling at Intellia Therapeutics
In other Intellia Therapeutics news, CEO John M. Leonard sold 26,807 shares of the firm's stock in a transaction that occurred on Friday, January 3rd. The stock was sold at an average price of $12.18, for a total value of $326,509.26. Following the sale, the chief executive officer now directly owns 941,115 shares of the company's stock, valued at approximately $11,462,780.70. This trade represents a 2.77 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Over the last three months, insiders have sold 29,000 shares of company stock valued at $352,551. Company insiders own 3.20% of the company's stock.
Hedge Funds Weigh In On Intellia Therapeutics
Hedge funds and other institutional investors have recently made changes to their positions in the company. GF Fund Management CO. LTD. purchased a new position in shares of Intellia Therapeutics in the fourth quarter valued at approximately $25,000. Sterling Capital Management LLC lifted its position in Intellia Therapeutics by 866.2% during the fourth quarter. Sterling Capital Management LLC now owns 3,198 shares of the company's stock worth $37,000 after buying an additional 2,867 shares in the last quarter. Whipplewood Advisors LLC acquired a new stake in Intellia Therapeutics during the fourth quarter worth $40,000. Resona Asset Management Co. Ltd. acquired a new stake in Intellia Therapeutics during the fourth quarter worth $43,000. Finally, Jones Financial Companies Lllp increased its stake in Intellia Therapeutics by 140.9% during the fourth quarter. Jones Financial Companies Lllp now owns 3,898 shares of the company's stock worth $45,000 after acquiring an additional 2,280 shares during the last quarter. Hedge funds and other institutional investors own 88.77% of the company's stock.
About Intellia Therapeutics
(
Get Free Report)
Intellia Therapeutics, Inc, a genome editing company, focuses on the development of curative therapeutics. The company's in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis; NTLA-2002 for the treatment of hereditary angioedema; and NTLA-3001 for alpha-1 antitrypsin deficiency associated lung disease.
See Also
Before you consider Intellia Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Intellia Therapeutics wasn't on the list.
While Intellia Therapeutics currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Thinking about investing in Meta, Roblox, or Unity? Enter your email to learn what streetwise investors need to know about the metaverse and public markets before making an investment.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
